Wuhan Kaidejinuo Biotechnology

Wuhan Kaidejinuo Biotechnology is a clinical-stage biotechnology company specializing in the development of AAV-based gene therapies for ophthalmic and genetic disorders. Founded by Professor Li Bin, the company is a pioneer in the field of mitochondrial gene therapy, particularly for the treatment of Leber Hereditary Optic Neuropathy (LHON). The company's lead candidate, rAAV-ND4, was one of the first gene therapies to undergo clinical evaluation in China and has demonstrated significant efficacy in restoring vision in patients with the ND4 mutation. Wuhan Kaidejinuo Biotechnology operates in close affiliation with Neurophth Therapeutics, serving as a key entity in the early research and clinical validation of their gene therapy pipeline.